A Phase 2 interventional study of Cohort A: vilobelimab and Cohort A: placebo in Acute Respiratory Distress Syndrome (ARDS), ARDS and ARDS (Acute Respiratory Distress Syndrome), sponsored by PPD Development, LP. Recruiting at 41 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by PPD Development, LP · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 324 studies in Respiratory Distress Syndrome with a site in United States — 46 open to participants now, 56 under way, 7 of them phase 3. Respiratory Distress Syndrome · United States.
Among the 324 studies in Respiratory Distress Syndrome with a site in United States, this one is the 19th largest by planned enrollment of the 250 interventional ones that give a count, is one of 14 that started in 2025, is one of 74 in phase 2, reaches primary completion later than 35 of the 55 other live ones, and was the 300th registered.
1,387 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →46 of the 324 studies in Respiratory Distress Syndrome with a site in United States are open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 7 days–30 days
Ohio State University · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 0 hrs–72 hrs
Massachusetts General Hospital · Sites in United States
Ages 18–80
Implicit Bioscience · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 193 Respiratory Distress Syndrome studies recruiting now, 117 (61%) set no upper age limit and 48 (25%) stop at 75 or younger; 50 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
324 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 101 · Phase 3 46 · Phase 4 6
First in 1991; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 60 across 822 interventional studies indexed under Respiratory Distress Syndrome.
Median enrollment 52 across the 250 interventional studies, 85 across the 68 observational. Of the 220 that completed or were terminated, 101 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 324 have an industry lead sponsor. The 10 most frequent:
PPD Development, LP is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
PPD Development, LP has 4 studies filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
20 of the studies in Respiratory Distress Syndrome with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06776783Phase 3Aerogen Pharma LimitedSafety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome | 2027-05 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05354141Phase 3Direct Biologics, LLCExtracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS) | 2027-11-30 |
| NCT04369599Emory UniversityTrans Thoracic Manipulation of Ventilation/Perfusion: the V/Q System | 2026-11 |
| NCT07674953University of ArkansasHow Different Levels of CPAP Affect Oxygen Delivery and Lung Expansion in Preterm Infants | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 324 studies in Respiratory Distress Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Participants will be randomized to receive either a placebo or one of the active treatments.
This record describes the default procedures and analyses for all cohorts. Each specific cohort may have additional eligibility requirements, safety and efficacy procedures, or endpoints, which will be described in the corresponding intervention-specific records on clinicaltrials.gov listed below in the detailed description.
This is a master protocol for a Phase 2 platform clinical trial to evaluate host-directed therapeutic candidates (i.e., investigational product, IP) for the treatment of hospitalized participants diagnosed with ARDS. The safety and efficacy of each IP will be studied within its own cohort (IP versus Placebo). All patients will continue to receive standard treatments for ARDS as per the investigator. An individual participant will complete the study in approximately 90 days. The study will include a screening period (\<24 hours from providing informed consent to treatment), in-hospital treatment period with IP/placebo starting on Day 1 through discharge from the hospital, and a follow-up period after discharge from the hospital through the end of study (Day 90 + 2 weeks).
Outcome data will be assembled for each patient over time (such as ventilatory status, oxygenation, and survival). Functional status using the WHO Ordinal scale and Karnofsky scale will be collected. Resource utilization will be calculated (length of stay in a critical care setting, days intubated, and survival).
All participants will undergo a series of physical exams, laboratory assessments/biomarker collections, ECG, Chest X-ray or CT scan, and questionnaires through Day 90. Exploratory biomarkers will be evaluated over time to facilitate clinical learning.
For information specific to each intervention included in this platform trial, please refer to the below corresponding, separate, clinicaltrials.gov records:
Vilobelimab NCT06701682 ; Paridiprubart NCT06701669 ; Bevacizumab NCT06701656
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each participant must meet all of the following criteria to be enrolled in this study:
Note that participants on noninvasive ventilation may be screened.
Exclusion Criteria
Participants will be excluded from the study if any of the following apply:
Participant with concurrent infections or history of the following:
Participant may have additional cohort-specific requirements.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Cohort A: vilobelimab
Drug: Cohort A: placebo
Drug: Cohort B: paridiprubart
Drug: Cohort B: placebo
Drug: Cohort C: bevacizumab
Drug: Cohort C: placebo
Administered as an IV formulation of 800 mg per dose and up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
Administered as an IV formulation of placebo of up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
Administered as a single IV dose of 15 mg/kg up to maximum of 1440 mg on Day 1
Administered as a single IV dose of placebo on Day 1
Administered as a single IV dose of 500 mg on Day 1
Administered as a single IV dose of placebo on Day 1
All-cause mortality (ACM) rate at Day 28
Time frame: Day 28
ACM at Day 60 and Day 90
Time frame: Day 60 and Day 90
ACM+ at Day 28, Day 60, and Day 90
Note: ACM+ composite score will be constructed by combining ACM and participant-relevant, infection-related Adverse Events (AE) and Serious Adverse Events (SAEs) from the MedDRA toxic/septic shock standardized MedDRA queries (SMQ).
Time frame: Day 28, Day 60, and Day 90
Improvements in oxygenation measured as change from baseline in PaO2/FiO2 ratio up to and including Day 28 (or discharge, whichever is earlier)
Time frame: Up to and including Day 28 or until Discharge (whichever is earlier)
Incidence of new invasive mechanical ventilation use during the study up to and including Day 28
Time frame: Up to and including Day 28
Ventilator-free days up to and including Day 28
Time frame: Up to and including Day 28
Proportion of participants alive and free of mechanical ventilation at Days 28, 60, and 90
Time frame: Days 28, 60, and 90
Time to recover gas exchange to a PaO2/FiO2 ≥ 300 measured on 2 consecutive days during the first 28 days after informed consent
Time frame: Up to and including Day 28
Extracorporeal Membrane Oxygenation (ECMO) free days up to and including Day 28
Time frame: up to and including Day 28
Incidence of participants with new ECMO use during the study up to and including Day 28.
Time frame: up to and including Day 28
Proportion of participants alive and free of ECMO at Days 28, 60, and 90
Time frame: Days 28, 60, and 90.
Proportion of participants achieving a ≥2-point improvement from baseline in the World Health Organization (WHO) 8-levels ordinal scale (from 0-8)
Time frame: While Hospitalized (up to 90 days)
Time to an improvement of one category and two categories from baseline using the WHO 8-levels ordinal scale (from 0-8) at Days 28, 60, and 90 (while hospitalized)
Time frame: While Hospitalized (up to 90 days)
Mean change in the WHO 8-levels ordinal scale from baseline through Day 90 (while hospitalized)
Time frame: While Hospitalized (up to 90 days)
Proportion of participants who improve clinical status as measured by the Karnofsky scale
The Karnofsky scale is used to assess the general condition of the patient. Scores range from 0 to 100 with higher scores indicating better functional ability.
Time frame: Post hospitalization through Day 90
Days of hospitalization up to and including Day 28
Time frame: up to and including Day 28
Days of ICU stay up to and including Day 28
Time frame: up to and including Day 28
Change in Short Form Health Survey (SF-12) from hospital discharge to Day 60 and to Day 90
The SF-12 is a self-reported outcome measure composed by 12 items which examine eight dimensions of physical and mental health. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.
Time frame: From hospital discharge to Day 60 and to Day 90
Change in St. George's Respiratory Questionnaire (SGRQ) from hospital discharge to Day 60 and to Day 90
The SGRQ comprises of 50 items and consists of two parts. The first part pertains to symptoms and the second pertains to functional status as well as social and psychological impact of disease. Overall scores range between 0 and 100 with higher scores indicating more limitations.
Time frame: From hospital discharge to Day 60 and to Day 90
Incidence and severity of adverse events (AEs) /adverse event of special interest (AESI) / serious adverse event (SAEs)
Time frame: Through Day 90
Not enrolling at this site — choose another above.
Started Jun 2025 (actual). Primary completion is estimated for Jul 2028, 37 months after the start.
Of 59 phase 2 interventional studies under Respiratory Distress Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 37 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vilobelimab · NI-0101 · Bevacizumab
Respiratory Distress Syndrome →
PPD Development, LP